INSMED INC Revenue
INSMED INC (INSM) reported Revenue of $425.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- INSMED INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $425.49M, a 296.11% increase year-over-year.
- INSMED INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $305.96M, a 229.62% increase year-over-year.
- INSMED INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $263.84M, a 152.62% increase year-over-year.
- INSMED INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $142.34M, a 52.36% increase year-over-year.
- INSMED INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $606.42M, a 66.73% increase from fiscal 2024.
- INSMED INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $363.71M, a 19.17% increase from fiscal 2023.
- INSMED INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $305.21M, a 24.39% increase from fiscal 2022.
- INSMED INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $245.36M, a 30.19% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $425.49M 10-Q · filed 2026-08-06 | $731.45M 10-Q · filed 2026-08-06 | $995.29M derived: sum of 3 quarters · filed 2026-08-06 | $1.14B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $305.96M 10-Q · filed 2026-05-07 | $569.81M derived: sum of 2 quarters · filed 2026-05-07 | $712.15M derived: sum of 3 quarters · filed 2026-05-07 | $819.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $263.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $406.19M derived: sum of 2 quarters · filed 2026-02-19 | $513.60M derived: sum of 3 quarters · filed 2026-08-06 | $606.42M 10-K · filed 2026-02-19 |
| 2025-09-30 | $142.34M 10-Q · filed 2025-10-30 | $249.76M derived: sum of 2 quarters · filed 2026-08-06 | $342.58M 10-Q · filed 2025-10-30 | $447.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $107.42M 10-Q · filed 2026-08-06 | $200.24M 10-Q · filed 2026-08-06 | $304.68M derived: sum of 3 quarters · filed 2026-08-06 | $398.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $92.82M 10-Q · filed 2026-05-07 | $197.26M derived: sum of 2 quarters · filed 2026-05-07 | $290.69M derived: sum of 3 quarters · filed 2026-05-07 | $381.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $104.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $197.87M derived: sum of 2 quarters · filed 2026-02-19 | $288.21M derived: sum of 3 quarters · filed 2026-02-19 | $363.71M 10-K · filed 2026-02-19 |
| 2024-09-30 | $93.42M 10-Q · filed 2025-10-30 | $183.76M derived: sum of 2 quarters · filed 2025-10-30 | $259.26M 10-Q · filed 2025-10-30 | $342.96M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $90.34M 10-Q · filed 2025-08-07 | $165.84M 10-Q · filed 2025-08-07 | $249.53M derived: sum of 3 quarters · filed 2026-02-19 | $328.61M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $75.50M 10-Q · filed 2025-05-08 | $159.19M derived: sum of 2 quarters · filed 2026-02-19 | $238.26M derived: sum of 3 quarters · filed 2026-02-19 | $315.49M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $83.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $162.76M derived: sum of 2 quarters · filed 2026-02-19 | $239.99M derived: sum of 3 quarters · filed 2026-02-19 | $305.21M 10-K · filed 2026-02-19 |
| 2023-09-30 | $79.07M 10-Q · filed 2024-10-31 | $156.30M derived: sum of 2 quarters · filed 2024-10-31 | $221.51M 10-Q · filed 2024-10-31 | $280.81M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $77.23M 10-Q · filed 2024-08-08 | $142.44M 10-Q · filed 2024-08-08 | $201.74M derived: sum of 3 quarters · filed 2025-02-20 | $269.47M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $65.21M 10-Q · filed 2024-05-09 | $124.51M derived: sum of 2 quarters · filed 2025-02-20 | $192.24M derived: sum of 3 quarters · filed 2025-02-20 | $257.46M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $59.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $127.03M derived: sum of 2 quarters · filed 2025-02-20 | $192.25M derived: sum of 3 quarters · filed 2025-02-20 | $245.36M 10-K · filed 2025-02-20 |
| 2022-09-30 | $67.73M 10-Q · filed 2023-10-26 | $132.95M derived: sum of 2 quarters · filed 2023-10-26 | $186.06M 10-Q · filed 2023-10-26 | $242.18M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $65.22M 10-Q · filed 2023-08-03 | $118.33M 10-Q · filed 2023-08-03 | $174.45M derived: sum of 3 quarters · filed 2024-02-22 | $221.21M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $53.11M 10-Q · filed 2023-05-04 | $109.23M derived: sum of 2 quarters · filed 2024-02-22 | $155.99M derived: sum of 3 quarters · filed 2024-02-22 | $201.35M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $56.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $102.88M derived: sum of 2 quarters · filed 2024-02-22 | $148.25M derived: sum of 3 quarters · filed 2024-02-22 | $188.46M 10-K · filed 2024-02-22 |
| 2021-09-30 | $46.76M 10-Q · filed 2022-10-27 | $92.12M derived: sum of 2 quarters · filed 2022-10-27 | $132.34M 10-Q · filed 2022-10-27 | $173.75M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $45.37M 10-Q · filed 2022-08-04 | $85.58M 10-Q · filed 2022-08-04 | $127.00M derived: sum of 3 quarters · filed 2023-02-23 | $170.64M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $40.21M 10-Q · filed 2022-05-05 | $81.63M derived: sum of 2 quarters · filed 2023-02-23 | $125.27M derived: sum of 3 quarters · filed 2023-02-23 | $167.77M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $41.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $85.06M derived: sum of 2 quarters · filed 2023-02-23 | $127.55M derived: sum of 3 quarters · filed 2023-02-23 | $164.41M 10-K · filed 2023-02-23 |
| 2020-09-30 | $43.64M 10-Q · filed 2021-10-28 | $86.14M derived: sum of 2 quarters · filed 2021-10-28 | $123.00M 10-Q · filed 2021-10-28 | $168.71M derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | $42.49M 10-Q · filed 2021-08-05 | $79.36M 10-Q · filed 2021-08-05 | $125.06M derived: sum of 3 quarters · filed 2021-08-05 | $163.95M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $36.86M 10-Q · filed 2021-05-06 | $82.57M derived: sum of 2 quarters · filed 2021-05-06 | $121.45M derived: sum of 3 quarters · filed 2021-05-06 | $151.43M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $45.71M 10-K · filed 2020-02-25 | $84.59M derived: sum of 2 quarters · filed 2020-10-29 | $114.56M derived: sum of 3 quarters · filed 2020-10-29 | $136.47M 10-K · filed 2022-02-17 |
| 2019-09-30 | $38.88M 10-Q · filed 2020-10-29 | $68.86M derived: sum of 2 quarters · filed 2020-10-29 | $90.76M 10-Q · filed 2020-10-29 | $100.59M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $29.97M 10-Q · filed 2020-08-06 | $51.87M 10-Q · filed 2020-08-06 | $61.71M derived: sum of 3 quarters · filed 2020-08-06 | $61.71M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $21.90M 10-Q · filed 2020-04-30 | $31.74M derived: sum of 2 quarters · filed 2020-04-30 | $31.74M derived: sum of 3 quarters · filed 2020-04-30 | $31.74M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | $9.84M 10-K · filed 2020-02-25 | $9.84M derived: sum of 2 quarters · filed 2020-02-25 | $9.84M derived: sum of 3 quarters · filed 2020-02-25 | $9.84M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 10-K · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 10-Q · filed 2019-10-30 | $0.00 derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $0.00 10-K · filed 2020-02-25 | $0.00 10-Q · filed 2019-08-01 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $0.00 derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $0.00 10-K · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $0.00 derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | $0.00 10-K · filed 2020-02-25 |
| 2017-09-30 | $0.00 10-K · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | |
| 2017-06-30 | $0.00 10-K · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | ||
| 2017-03-31 | $0.00 10-K · filed 2019-02-22 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |